Eli Lilly and Company and Incyte Corp. announced results from the Phase 3 RA-BEACON study of baricitinib in patients with active rheumatoid arthritis (RA). Baricitinib is an orally available Janus kinase (JAK) 1 and JAK2 inhibitor being studied for use in the treatment of certain autoimmune conditions, including RA.
The RA-BEACON study included 527 patients with moderately-to-severely active RA who previously failed one or more tumor necrosis factor (TNF) inhibitors and who were taking stable doses of conventional disease-modifying anti-rheumatic drug (cDMARD) therapy. Patients received either one of two doses of once daily baricitinib or placebo in addition to their background conventional disease-modifying anti-rheumatic drug therapy (cDMARDs). Results demonstrated that the primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment has been met.
The results of several ongoing Phase 3 studies conducted by Lilly and Incyte will be announced in 2015.